Prognostic significance of high podoplanin expression after chemoradiotherapy in esophageal squamous cell carcinoma patients

Journal of Surgical Oncology

Volumn 105, Issue 2, 2012, Pages 183-188

  Chao, Yin Kai ^a   Chuang, Wen Yu ^a   Yeh, Chi Ju ^a   Wu, Yi Cheng ^a   Liu, Yun Hen ^a   Hsieh, Ming Ju ^a   Cheng, Ann Joy ^a   Hsueh, Chuen ^a   Liu, Hui Ping ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

chemoradiotherapy; esophageal cancer; podoplanin

Indexed keywords

CISPLATIN; FLUOROURACIL; PODOPLANIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; ILLNESS TRAJECTORY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84855357168     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22068     Document Type: Article

References (23)

1. Gebski V, Burmeister B, Smithers BM, et al.: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 2007; 8: 226-234. (Pubitemid 46291702)
2. Berger AC, Farma J, Scott WJ, et al.: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330-4337. (Pubitemid 46207006)
3. Stahl M, Wilke H, Stuschke M, et al.: Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol 2005; 131: 67-72.
4. Edge SB, Byrd DR, Compton CC, et al.: AJCC Cancer Staging Manual. 7th edition. New York, NY: Spring-Verlag; 2010.
5. Schoppmann SF, Birner P, Studer P, et al.: Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res 2001; 21: 2351-2355. (Pubitemid 33054395)
6. Cueni LN, Hegyi I, Shin JW, et al.: Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol 2010; 177: 1004-1016.
7. Martin-Villar E, Megias D, Castel S, et al.: Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 2006; 119: 4541-4553. (Pubitemid 44830653)
8. Schacht V, Dadras SS, Johnson LA, et al.: Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005; 166: 913-921. (Pubitemid 40315647)
9. Wicki A, Christofori G,: The potential role of podoplanin in tumour invasion. Br J Cancer 2007; 96: 1-5. (Pubitemid 46094630)
10. Wicki A, Lehembre F, Wick N, et al.: Tumor invasion in the absence of epithelial-mesenchymal transition: Podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006; 9: 261-272.
11. Huber GF, Fritzsche FR, Zullig L, et al.: Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx. Int J Cancer 2011; 129: 1404-1409.
12. Ito T, Ishii G, Nagai K, et al.: Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies. Lung Cancer 2009; 63: 418-424.
13. Yuan P, Temam S, El-Naggar A, et al.: Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006; 107: 563-569. (Pubitemid 44107217)
14. Dumoff KL, Chu CS, Harris EE, et al.: Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiation. Mod Pathol 2006; 19: 708-716.
15. Wang WL, Lee CT, Lee YC, et al.: Risk factors for developing synchronous esophageal neoplasia in patients with head and neck cancer. Head Neck 2010; 33: 77-81.
16. Lee KD, Lu CH, Chen PT, et al.: The incidence and risk of developing a second primary esophageal cancer in patients with oral and pharyngeal carcinoma: A population-based study in Taiwan over a 25 year period. BMC Cancer 2009; 9: 373.
17. Chuang WY, Yeh CJ, Wu YC, et al.: Tumor cell expression of podoplanin correlates with nodal metastasis in esophageal squamous cell carcinoma. Histol Histopathol 2009; 24: 1021-1027.
18. Mandard AM, Dalibard F, Mandard JC, et al.: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686. (Pubitemid 24166250)
19. Royal College of Pathologists. Dataset for the Histopathological Reporting of Oesophageal Carcinoma. 2nd edition. London, England: The Royal College of Pathologists; 2006.
20. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, et al.: Podoplanin: A novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 2008; 26: 354-360. (Pubitemid 351171684)
21. Rahadiani N, Ikeda J, Makino T, et al.: Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma. Ann Surg Oncol 2010; 17: 1311-1323.
22. Yeh CJ, Chuang WY, Chao YK, et al.: High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma. Virchows Arch 2011; 458: 171-178.
23. Chao YK, Yeh CJ, Chang HK, et al.: Impact of circumferential resection margin distance on locoregional recurrence and survival after chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol 2011; 18: 529-534.